We also demonstrate that a DNA-only, less than 50-gene next-generation sequencing (sNGS) panel combined with ultra-rapid reflex testing via Idylla Genefusion assay provides a cost-effective testing schema for most lung cancer cases, thereby largely negating the need for upfront ALK and ROS1 fusion testing by FISH. The gene discussed is ROS1; the disease is lung carcinoma.